EGFRvIII-targeted vaccination therapy of malignant glioma

Brain Pathology

Volumn 19, Issue 4, 2009, Pages 713-723

  Choi, Bryan D ^a   Archer, Gary E ^a   Mitchell, Duane A ^a   Heimberger, Amy B ^b   McLendon, Roger E ^a   Bigner, Darell D ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antigens; Central nervous system neoplasms; Epidermal growth factor receptor; Immunotherapy

Indexed keywords

ANASPEC; BIOSYN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; KEYHOLE LIMPET HEMOCYANIN; PEPTIDE VACCINE; TEMOZOLOMIDE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; BLOOD BRAIN BARRIER; CANCER CELL; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; EXTERNAL BEAM RADIOTHERAPY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTOPENIA; NONHUMAN; TREATMENT OUTCOME; VACCINATION;

BRAIN NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 69949120572     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2009.00318.x     Document Type: Conference Paper

References (109)

1. Aloisi F, Ria F, Adorini L (2000) Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 21 : 141 147.
2. Antonyak MA, Moscatello DK, Wong AJ (1998) Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem 273 : 2817 2822.
3. Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P et al (2001) Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med 7 : 369 372.
4. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H et al (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6 : 916 919.
5. Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, Bigner DD (1995) Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene. Cell Growth Differ 6 : 1251 1259.
6. Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G (2007) Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 39 : 1416 1431.
7. Bickel U (1995) Antibody delivery through the blood-brain barrier. Adv Drug Deliv Rev 15 : 53 72.
8. Bigner DD (1981) Biology of gliomas: potential clinical implications of glioma cellular heterogeneity. Neurosurgery 9 : 320 326.
9. Bigner DD, Schold C, Bigner SH, Bullard DE, Wikstrand C (1981) How heterogeneous are gliomas? Cancer Treat Rep 65 (Suppl. 2 45 49.
10. Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD (1990) Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50 : 8017 8022.
11. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P et al (1995) BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2 : 167 175.
12. Boockvar JA, Kapitonov D, Kapoor G, Schouten J, Counelis GJ, Bogler O et al (2003) Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci 24 : 1116 1130.
13. Brendza RP, Holtzman DM (2006) Amyloid-beta immunotherapies in mice and men. Alzheimer Dis Assoc Disord 20 : 118 123.
14. Carpenter G, Cohen S (1990) Epidermal growth factor. J Biol Chem 265 : 7709 7712.
15. CBTRUS (2008) Statistical report: primary brain tumors in The United States, 2000-2004. Published by The Central Brain Tumor Registry of The United States.
16. Cebon J, Jager E, Shackleton MJ, Gibbs P, Davis ID, Hopkins W et al (2003) Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun 3 : 7.
17. Chu CT, Everiss KD, Wikstrand CJ, Batra SK, Kung HJ, Bigner DD (1997) Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem J 324 : 855 861.
18. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH et al (2002) Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62 : 3347 3350.
19. Cserr HF, Knopf PM (1992) Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 13 : 507 512.
20. Curran WJ Jr., Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85 : 704 710.
21. Dalmau J, Rosenfeld MR (2008) Paraneoplastic syndromes of the CNS. Lancet Neurol 7 : 327 340.
22. Day ED, Lassiter S, Woodhall B, Mahaley JL, Mahaley MS Jr. (1965) The localization of radioantibodies in human brain tumors. I. Preliminary exploration. Cancer Res 25 : 773 778.
23. de Vries HE, Kuiper J, de Boer AG, Van Berkel TJ, Breimer DD (1997) The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev 49 : 143 155.
24. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98 : 8850 8855.
25. Deshpande SS, Angkeow P, Huang J, Ozaki M, Irani K (2000) Rac1 inhibits TNF-alpha-induced endothelial cell apoptosis: dual regulation by reactive oxygen species. FASEB J 14 : 1705 1714.
26. Duff K (1999) Curing amyloidosis: will it work in humans? Trends Neurosci 22 : 485 486.
27. Ehrlich P, Bolduan C (1906) Collected Studies on Immunity, 1st edn. J. Wiley & Sons : New York.
28. Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP (1991) Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51 : 2164 2172.
29. Engelhardt B, Ransohoff RM (2005) The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 26 : 485 495.
30. Fabry Z, Raine CS, Hart MN (1994) Nervous tissue as an immune compartment: the dialect of the immune response in the CNS. Immunol Today 15 : 218 224.
31. Feldkamp MM, Lala P, Lau N, Roncari L, Guha A (1999) Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 45 : 1442 1453.
32. Frederick L, Wang XY, Eley G, James CD (2000) Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60 : 1383 1387.
33. Freund J (1930) Accumulation of antibodies in the central nervous system. J Exp Med 51 : 889 902.
34. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A et al (2007) Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21 : 2683 2710.
35. Gehrmann J, Matsumoto Y, Kreutzberg GW (1995) Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev 20 : 269 287.
36. Gilboa E (1999) The makings of a tumor rejection antigen. Immunity 11 : 263 270.
37. Gilboa E (2004) The promise of cancer vaccines. Nat Rev Cancer 4 : 401 411.
38. Goldmann J, Kwidzinski E, Brandt C, Mahlo J, Richter D, Bechmann I (2006) T cells traffic from brain to cervical lymph nodes via the cribroid plate and the nasal mucosa. J Leukoc Biol 80 : 797 801.
39. Hardy J (1997) Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci 20 : 154 159.
40. Hart DN, Fabre JW (1981) Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain. J Exp Med 154 : 347 361.
41. Heimberger A, Hussain SF, Aldape K, Sawaya R, Archer GA, Friedman H et al (2006) Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. J Clin Oncol 24 : abstr 2529.
42. Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS et al (2002) Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery 50 : 158 164 discussion 64-66.
43. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand CJ, Friedman AH et al (2003) Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 9 : 4247 4254.
44. Hickey WF (1991) Migration of hematogenous cells through the blood-brain barrier and the initiation of CNS inflammation. Brain Pathol 1 : 97 105.
45. Hou ST, Wang CC, Chu ML (1997) Ribotyping and random amplification of polymorphic DNA for nosocomial Enterobacter cloacae isolates in a pediatric intensive-care unit. Infect Control Hosp Epidemiol 18 : 769 771.
46. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, Archer GE et al (1990) Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci USA 87 : 4207 4211.
47. Imperato JP, Paleologos NA, Vick NA (1990) Effects of treatment on long-term survivors with malignant astrocytomas. Ann Neurol 28 : 818 822.
48. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J et al (2000) Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 97 : 12198 12203.
49. Jaros E, Perry RH, Adam L, Kelly PJ, Crawford PJ, Kalbag RM et al (1992) Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer 66 : 373 385.
50. Kass E, Schlom J, Thompson J, Guadagni F, Graziano P, Greiner JW (1999) Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res 59 : 676 683.
51. Koller MF, Mohajeri MH, Huber M, Wollmer MA, Roth Z'graggen BV, Sandmeier E et al (2004) Active immunization of mice with an Abeta-Hsp70 vaccine. Neurodegener Dis 1 : 20 28.
52. Kuan CT, Wikstrand CJ, Bigner DD (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8 : 83 96.
53. Lahiri DK, Chen DM, Lahiri P, Bondy S, Greig NH (2005) Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases. Ann N Y Acad Sci 1056 : 430 449.
54. Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS et al (2004) Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity. Clin Cancer Res 10 : 6732 6743.
55. Lammering G, Valerie K, Lin PS, Hewit TH, Schmidt-Ullrich RK (2004) Radiation-induced activation of a common variant of EGFR confers enhanced radioresistance. Radiother Oncol 72 : 267 273.
56. Lengauer C, Kinzler KW, Vogelstein B (1998) Genetic instabilities in human cancers. Nature 396 : 643 649.
57. Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D et al (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102 : 16013 16018.
58. Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H et al (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313 : 144 147.
59. Loeb LA (2001) A mutator phenotype in cancer. Cancer Res 61 : 3230 3239.
60. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L et al (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155 : 853 862.
61. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH et al (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80 : 219 230.
62. Masson F, Calzascia T, Di Berardino-Besson W, de Tribolet N, Dietrich PY, Walker PR (2007) Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol 179 : 845 853.
63. McLendon RE, Turner K, Perkinson K, Rich J (2007) Second messenger systems in human gliomas. Arch Pathol Lab Med 131 : 1585 1590.
64. Medawar PB (1948) Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol 29 : 58 69.
65. Mitchell DA, Fecci PE, Sampson JH (2008) Immunotherapy of malignant brain tumors. Immunol Rev 222 : 70 100.
66. Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH (2008) Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neurooncol 10 : 10 18.
67. Mocellin S, Mandruzzato S, Bronte V, Marincola FM (2004) Cancer vaccines: pessimism in check. Nat Med 10 : 1278 1279 author reply 9-80.
68. Montgomery RB, Guzman J, O'Rourke DM, Stahl WL (2000) Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression. J Biol Chem 275 : 17358 17363.
69. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW et al (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55 : 5536 5539.
70. Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ (1998) Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J Biol Chem 273 : 200 206.
71. Moscatello DK, Ramirez G, Wong AJ (1997) A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res 57 : 1419 1424.
72. Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL (1990) The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 65 : 1619 1625.
73. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91 : 7727 7731.
74. Owens T, Renno T, Taupin V, Krakowski M (1994) Inflammatory cytokines in the brain: does the CNS shape immune responses? Immunol Today 15 : 566 571.
75. Pardridge WM (1991) Peptide Drug Delivery to the Brain. Raven Press : New York.
76. Pedersen MW, Tkach V, Pedersen N, Berezin V, Poulsen HS (2004) Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer 108 : 643 653.
77. Prigent SA, Nagane M, Lin H, Huvar I, Boss GR, Feramisco JR et al (1996) Enhanced tumorigenic behavior of glioblastoma cells expressing a truncated epidermal growth factor receptor is mediated through the Ras-Shc-Grb2 pathway. J Biol Chem 271 : 25639 25645.
78. Purev E, Cai D, Miller E, Swoboda R, Mayer T, Klein-Szanto A et al (2004) Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, Delta EGF-R, and de2-7 EGF-R). J Immunol 173 : 6472 6480.
79. Ransohoff RM, Kivisakk P, Kidd G (2003) Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 3 : 569 581.
80. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411 : 380 384.
81. Rosenberg SA (2004) Shedding light on immunotherapy for cancer. N Engl J Med 350 : 1461 1463.
82. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 : 909 915.
83. Sampson JH, Crotty LE, Lee S, Archer GE, Ashley DM, Wikstrand CJ et al (2000) Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci USA 97 : 7503 7508.
84. Sampson JH, Archer GE, Bigner D, Davis T, Friedman HS, Keler T et al (2008) Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J Clin Oncol 26 : abstr 2011.
85. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD (2008) Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 20 (5 267 275.
86. Sampson JH, Archer GE, Mitchell DA, Heimberger A, Herndon JE 2nd., Lally-Goss D et al (2009) An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme (submitted for publication).
87. Scheibenbogen C, Schmittel A, Keilholz U, Allgauer T, Hofmann U, Max R et al (2000) Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J Immunother 23 : 275 281.
88. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T et al (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 : 173 177.
89. Schmittling RJ, Archer GE, Mitchell DA, Heimberger A, Pegram C, Herndon JE et al (2008) Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods 339 : 74 81.
90. Scott AM, Lee FT, Tebbutt N, Herbertson R, Gill SS, Liu Z et al (2007) A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci USA 104 : 4071 4076.
91. Selkoe DJ (1999) Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399 (6738 Suppl. A23 A31.
92. Serot JM, Foliguet B, Bene MC, Faure GC (1997) Ultrastructural and immunohistological evidence for dendritic-like cells within human choroid plexus epithelium. Neuroreport 8 : 1995 1998.
93. Solomon B, Koppel R, Frankel D, Hanan-Aharon E (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 94 : 4109 4112.
94. St. George-Hyslop PH, Westaway DA (1999) Alzheimer's disease. Antibody clears senile plaques. Nature 400 : 116 117.
95. Stoscheck CM, King LE Jr. (1986) Functional and structural characteristics of EGF and its receptor and their relationship to transforming proteins. J Cell Biochem 31 : 135 152.
96. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987 996.
97. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 : 205 216.
98. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39 : 347 351.
99. Timmerman JM, Levy R (2004) Cancer vaccines: pessimism in check. Nat Med 10 : 1279 author reply 1279-80.
100. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182 : 689 698.
101. Van Pel A, Boon T (1982) Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci USA 79 : 4718 4722.
102. Vredenburgh JJ, Desjardins A, Herndon JE 2nd., Marcello J, Reardon DA, Quinn JA et al (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25 : 4722 4729. (Pubitemid 350086473)
103. Weinstein IB (2002) Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297 : 63 64.
104. Wikstrand CJ, Bigner SH, Bigner DD (1983) Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies. Cancer Res 43 : 3327 3334.
105. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD (1997) Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 57 : 4130 4140.
106. Wikstrand CJ, Reist CJ, Archer GE, Zalutsky MR, Bigner DD (1998) The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target. J Neurovirol 4 : 148 158.
107. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, Vogelstein B (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89 : 2965 2969.
108. Wu AH, Xiao J, Anker L, Hall WA, Gregerson DS, Cavenee WK et al (2006) Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol 76 : 23 30.
109. Zalutsky MR, Moseley RP, Coakham HB, Coleman RE, Bigner DD (1989) Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res 49 : 2807 2813.